Open Access"OLD IS THE NEW NORMAL"
Author(s) -
Gopakumar G. Nair
Publication year - 2021
Publication title -
indian drugs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.121
H-Index - 31
ISSN - 0019-462X
DOI - 10.53879/id.58.02.p0005
Subject(s) - repurposing , budesonide , medicine , inhaler , covid-19 , formoterol , intensive care medicine , business , medical emergency , inhalation , engineering , anesthesia , asthma , disease , infectious disease (medical specialty) , waste management
Dear Reader, “Every cloud has a silver lining”. A few “side effects” of the Covid era are welcome for diverse reasons. The “webinars explosion” on the internet and the new normal experience of “work from home” and online operations have produced “travel-saving”, “time-saving” and “overhead saving” economics in corporate and academic environs. More particularly, the new “innovation culture” that has emerged in the small-medium pharma sector as the response to the patient needs in the pandemic tsunami is a welcome development. In the wake of this repurposing spree, many “grandfather” drugs have found renewed interest. The revival of HCQ has been relatively short-lived compared to the “evergreen” Paracetamol which is being dispensed both to Covid patients in early stages and post vaccination to one and all. The medical profession as well as clinical researchers have taken to these proven remedies with low but well known (often nil) side effects. There are many examples. Recent research was shown that “Budesonide” inhaler (and the Budesonide and Formoterol inhalation) is an effective prophylactic as well as early stage Covid-19 therapy.